Table 4.

Subgroup analysis estimating the risk of MACE associated with GnRH antagonist comparing with GnRH agonist.

GnRH antagonist vs GnRH agonist	MACE				Composite CV events
	No of event	aHRa	(95% CI)	P value	No of event	aHR	(95% CI)	P value
Preexisting CVD, initial staging N=1 or M=1
GnRH antagonist (n = 106)	34	0.98a	(0.66–1.45)	0.9071	3	0.16b	(0.04–0.38)	0.013
GnRH agonist (n = 1489)	621				188
Receiving more than 6 months of ADT (GnRH antagonist ≥6 months vs GnRH agonist ≥6 months)
GnRH antagonist (n = 286)	82	0.95	(0.74–1.22)	0.7023	15	0.30	(0.16–0.54)	<0.0001
GnRH agonist (n = 10615)	3780				1637
Preexisting CVD, receiving more than 6 months of ADT (GnRH antagonist ≥6 months vs GnRH agonist ≥6 months)
GnRH antagonist (n = 96)	24	0.64c	(0.39–1.05)	0.0757	3	0.12d	(0.03–0.49)	0.0032
GnRH agonist (n = 2006)	687				375

aHR adjusted hazard ratio, CV cardiovascular, GnRH gonadotropin-releasing hormone, MACE major adverse cardiovascular event (ischemic heart disease, stroke, congestive heart failure or CV-related death).

preexising CV risk: receiving cardiac therapy, diagnosis of ischemic heart diseases, stroke, or congestive heart failure 1 year before androgen deprivation therapy initiation.

^aaHRs were estimated using cox model adjusted for age, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.

^baHRs were estimated using the Fine and Gray competing risk model adjusted for age receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.

^caHRs were estimated using cox model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.

^daHRs were estimated using the Fine and Gray competing risk model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.